Journal of Clinical Oncology· 2012Q1
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- 1,376citations
- Q1SCImago
- 2012year
Short summary
Adding bevacizumab (BV) to gemcitabine and carboplatin (GC) chemotherapy significantly improved progression-free survival (PFS) by 4.0 months (12.4 vs. 8.4 months) in patients with platinum-sensitive recurrent ovarian cancer.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Reproductive Medicine
Reproductive MedicineMedicine